Ocular Therapeutix, Inc.
OCUL
$10.04
-$0.06-0.59%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.48M | 10.79M | 13.25M | 14.54M | 13.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.48M | 10.79M | 13.25M | 14.54M | 13.46M |
| Cost of Revenue | 56.15M | 67.54M | 52.39M | 54.13M | 53.03M |
| Gross Profit | -42.67M | -56.76M | -39.14M | -39.59M | -39.57M |
| SG&A Expenses | 39.44M | 36.58M | 30.62M | 29.11M | 28.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 95.58M | 104.13M | 83.01M | 83.24M | 81.10M |
| Operating Income | -82.11M | -93.34M | -69.76M | -68.70M | -67.64M |
| Income Before Tax | -78.76M | -88.61M | -64.65M | -69.42M | -67.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -78.76M | -88.61M | -64.65M | -69.42M | -67.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -78.76M | -88.61M | -64.65M | -69.42M | -67.81M |
| EBIT | -82.11M | -93.34M | -69.76M | -68.70M | -67.64M |
| EBITDA | -80.26M | -92.06M | -68.51M | -67.63M | -66.62M |
| EPS Basic | -0.35 | -0.40 | -0.29 | -0.38 | -0.39 |
| Normalized Basic EPS | -0.22 | -0.25 | -0.18 | -0.24 | -0.25 |
| EPS Diluted | -0.35 | -0.40 | -0.29 | -0.38 | -0.39 |
| Normalized Diluted EPS | -0.22 | -0.25 | -0.18 | -0.24 | -0.25 |
| Average Basic Shares Outstanding | 224.95M | 224.10M | 222.92M | 183.92M | 172.59M |
| Average Diluted Shares Outstanding | 224.95M | 224.10M | 222.92M | 183.92M | 172.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |